Strategic Partnerships Leverage DiaSorin’s recent collaboration momentum with Inpeco, McKesson, and Thermo Fisher to position joint sales initiatives that expand distribution networks, streamline test workflows, and accelerate deployment of LIAISON and VERIGENE platforms in large clinical labs and hospital systems.

Global Expansion Capitalize on a broad international footprint and multinational product portfolio to target large reference laboratories and academic medical centers increasingly centralizing molecular diagnostics, particularly for respiratory, gastrointestinal, and bloodstream panels.

Precision Medicine Highlight leadership in precision medicine and companion diagnostics to engage biopharma and hospital networks seeking targeted panels and personalized testing strategies, offering integrated solutions across simple direct tests and syndromic panels.

High-Throughput Readiness Promote the scalability of the LIAISON MDX and VERIGENE platforms, emphasizing flexible 8-well to 96-well capabilities and sample-to-answer workflows to attract high-volume labs seeking efficient, automated molecular diagnostics.

Product Portfolio Growth Position ongoing product introductions such as CE-marked QuantiFERON-TB, Simplexa C. auris Direct, and future expanding menus as opportunities to upsell bundled testing solutions, service contracts, and training packages to hospital networks and laboratories upgrading their infectious disease testing menu.